AstraZeneca (AZN) Updates FY 2018 Earnings Guidance

AstraZeneca (NYSE:AZN) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.68. AstraZeneca also updated its FY18 guidance to $3.30-3.50 EPS.

Shares of AstraZeneca stock traded up $1.44 during trading on Thursday, reaching $40.65. The company’s stock had a trading volume of 5,475,700 shares, compared to its average volume of 4,026,371. AstraZeneca has a 52-week low of $31.99 and a 52-week high of $41.28. The stock has a market capitalization of $97.16 billion, a price-to-earnings ratio of 9.50, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.38. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The company had revenue of $5.34 billion during the quarter, compared to analysts’ expectations of $5.26 billion. During the same quarter in the prior year, the company earned $1.12 EPS. The firm’s revenue was down 14.3% on a year-over-year basis. On average, equities research analysts forecast that AstraZeneca will post 1.67 earnings per share for the current fiscal year.

AZN has been the subject of several analyst reports. Jefferies Financial Group cut shares of AstraZeneca from a buy rating to a hold rating in a research report on Thursday, August 16th. ValuEngine cut shares of AstraZeneca from a buy rating to a hold rating in a research report on Friday, September 7th. Wolfe Research initiated coverage on shares of AstraZeneca in a research report on Tuesday, October 23rd. They set an outperform rating for the company. Zacks Investment Research cut shares of AstraZeneca from a buy rating to a hold rating in a research report on Tuesday, October 16th. Finally, Guggenheim initiated coverage on shares of AstraZeneca in a research report on Monday, October 8th. They set a buy rating for the company. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $40.34.

In other news, major shareholder Plc Astrazeneca purchased 600,000 shares of the company’s stock in a transaction on Monday, October 22nd. The stock was acquired at an average price of $5.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

WARNING: “AstraZeneca (AZN) Updates FY 2018 Earnings Guidance” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply